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Background: Evidence is accumulating that, similar to other ventral hernias, umbilical and epigastric hernias must
be mesh repaired. The difficulties involved in mesh placement and in mesh-related complications could be the reason
many small abdominal hernias are still primary closed. In laparoscopic repair, a mesh is placed intraperitoneally,
while the most common procedure is open surgery is pre-peritoneal mesh placement. A recently developed
alternative method is the so-called patch repair, in this approach a mesh can be placed intraperitoneally through
open surgery. In theory, such patches are particularly suitable for small hernias due to a reduction in the required
dissection. This simple procedure is described in several studies. It is still unclear whether this new approach is
associated with an equal risk of recurrence and complications compared with pre-peritoneal meshes. The material
of the patch is in direct contact with intra-abdominal organs, it is unknown if this leads to more complications. On
the other hand, the smaller dissection in the pre-peritoneal plane may lead to a reduction in wound complications.
Methods/Design: 346 patients suffering from an umbilical or epigastric hernia will be included in a multi-centre
patient-blinded trial, comparing mesh repair with patch repair. Randomisation will take place for the two operation
techniques. The two devices investigated are a flat pre-peritoneal mesh and a Proceed Ventral Patch®. Stratification will
occur per centre. Post-operative evaluation will take place after 1, 3, 12 and 24 months. The number of complications
requiring treatment is the primary endpoint. Secondary endpoints are Verbal Descriptor Scale (VDS) pain score and VDS
cosmetic score, operation duration, recurrence and costs. An intention to treat analysis will be performed.
Discussion: This trial is one of the first in its kind, to compare different mesh devices in a randomized controlled
setting. The results will help to evaluate mesh repair for epigastric an umbilical hernia, and find a surgical method that
minimizes the complication rate.
Trial registration: Netherlands Trail Registration (NTR) www.trialregister.nl 2010 NTR2514 NL33995.060.10
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The evidence that umbilical and epigastric hernias must
be repaired using a mesh, in analogy with other hernias,
is accumulating [1-7]. The use of a mesh in large hernias
reduces the risk of recurrence from approximately 15-40%
to 1-10% [1,4-6,8-10]. However, less research has been
performed if this also applies for small hernias. To date,
most small hernias are still closed with primary sutures,
because of the sometimes-difficult pre-peritoneal plane
in which the mesh should be placed. Therefore, the
results of the Hernia Umbilicalis Mesh versus Primair
suture (HUMP) trial that focuses on hernias smaller than
2 centimetres will have great added value for umbilical
hernias in particular [11]. Other retrospective studies
suggest that for the reoperation rate due to recurrence
mesh is superior in umbilical and epigastric hernias [7].
In contrast to the HUMP trial, which places the mesh in
this pre-peritoneal plane, a mesh can also be placed in-
traperitoneally. Advantages of intraperitoneal mesh
placement can be shorter operation time. Intraperito-
neal mesh placement can also be done by a laparoscopic
approach [12-14]. Although in the laparoscopic mesh
placement, several new fascia openings in the abdom-
inal wall are created. The search for alternative tech-
niques without these additional fascia defects may have
played an important role in the development of these
so-called patches. Patches are small devices, which can
be inserted by open surgery and placed underneath the
peritoneum [15-17].
In theory, such patches are particularly suitable for
small hernias because of the lesser dissection necessary.
It is still unclear whether this simpler procedure is also
associated with at least an equal risk of recurrence and
complications compared to conventional mesh placement.
The ease of a surgical procedure is not a clear clinically
relevant parameter, but it does often play a significant role
in the surgeon’s choices. Not only are there implications
for approximately 4100 umbilical and 2400 epigastric
operations in the Netherlands per year [18], but also for
a frequently occurring other abdominal wall hernia, the
small incisional hernia.
The MORPHEUS trial is designed to clarify which
treatment for primary umbilical and epigastric hernias is
superior in terms of complications, costs and recurrence.Table 1 Inclusion criteria
Hernia related Patient related
In epigastric or (peri-)
umbilical region
Age 18 years or older
< 3 cm (2 fingers) Capacity (comprehension, language




The MORPHEUS trial is a multicentre, randomized con-
trolled, nationwide, patient-blinded, superiority study. Pa-
tients will be randomly allocated to undergo open flat
mesh repair or open patch repair for primary umbilical or
epigastric hernias. The aim of this study is to determine
the ideal treatment for patients with these conditions interms of operation related complication and postopera-
tive pain.
Objectives/Endpoints
The primary objective of the MORPHEUS trial is to
evaluate whether a ventral patch is associated with fewer
complications than in conventional mesh placement for
epigastric and umbilical repair. A complication is defined
as an undesired development that requires treatment.
Complications will be recorded up to three months after
the initial procedure and pain up to 24 months post-
operative. Secondary endpoints are differences in recur-
rence, cosmetic score, operation duration and costs.
Participants
The institutional review board of each participating
hospital has approved this randomized controlled trial.
Inclusion started February the 1st 2011. Adult patients
with a single primary umbilical or epigastric hernia
qualify for participation in the study. Patients with in-
carcerated hernia are also included. The maximum size
of the herniation orifice can be 3 cm, corresponding
with 2 fingers in analogy with the European Herniation
Society (EHS) classification for inguinal hernias [19].
Patients with diagnosed ascites are excluded. This also
applies for patients who cannot sufficiently understand
and/or follow through participation in a trial. For the
related selection criteria see Table 1.
Possible participants receive verbal and written informa-
tion about the trial, which includes an informed consent
form. Those who participate must sign the informed con-
sent form, which must also be signed by the investigator.
If a patient does not participate in the trial, the reason for
this must be stated. A patient included in the trial is re-
quested to fill in a questionnaire (P1) before the operation.
Interventions
All procedures will take place under general anaesthesia.
Administering a local anaesthetic peri-operatively is rec-
ommended. Prophylactic antibiotics are given on indica-
tion only. The use of a steri-drape as well as drains is not
advised. Enlarging the herniation orifice as well as closing
fascia over the mesh is permitted for both techniques.
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umbilical or median incision across the hernia, then dis-
section of the fascia and mobilisation of the hernia sac.
Opening of the hernia sac for inspection is permitted.
Dissection of the pre-peritoneal area takes place after
repositioning of the hernia. A flat large pore and light-
weight polypropylene mesh with a minimum diameter
of 6 cm is placed. Fixation of the mesh is carried out
with non-absorbable monofilament sutures.
For the patch procedure, the hernia sac is opened.
Possible adhesions must be released intraperitoneally.
The patch is placed underneath the peritoneum, the
slips fixed to the fascia. If in the surgeon’s opinion the
hernia sac can be repositioned without opening it, place-
ment is also permitted in the pre-peritoneal plane. We
have chosen the standard of a PROCEED™ VENTRAL
PATCH (Ethicon, Norderstedt, Germany) for this trial.
No specific brand was chosen for the flat large pore and
lightweight polypropylene mesh.Figure 1 Trial flow-chart.Follow-up and flow chart protocol
The surgeon must fill in a questionnaire (D1) immedi-
ately after the operation. The patients are advised to
take 1 gram of paracetamol 3 times a day for the first
2 weeks, and to begin mobilizing immediately according
to their capacity. Follow-up at the outpatient clinic
takes place after 1 and 12 months, with the practitioner
filling in the questionnaires (D2 and D3). The patients
are asked to fill in a questionnaire 3 and 24 months
after the operation (P2 and P3). These questionnaires
will be sent to the patients by postal service or e-mail.
Non-responders were contacted up to three times by
means of a telephone questionnaire. Figure 1 shows the
studies flow-chart.Calculation of random sample size
The primary outcome is the number of complications that
require treatment. These are defined in detail further in
the protocol. The occurrence of complications up to 23%
is described [4]. Trials involving patch repair report a
much lower complication rate, but the number of trials is
significantly less. It is assumed that a conventional proced-
ure leads to a complication in 20% of the cases [4,20]. The
hypothesis is that this is reduced to 10% if a patch is used
for repair. At a significance level of 5% and a power of
90%, the random sample size is 137 patients per group in
a bilateral t-test. In the result analysis a Mann–Whitney
parametric test will be used to evaluate a normal distri-
bution. Therefore, the sample size must be increased by
15% [21]. Taking a minimum of 10% loss-to-follow-up
into account as well, the total number of patients to be
randomized becomes 346.Participant recruitment and retention
The surgeon will recruit the patients. Participation is not
stimulated in any way other than voluntary participation.
Randomisation
Sequence generation and randomisation will be performed
by http://www.random.org/. The generated sequence is
printed on paper cards with randomization numbers. These
cards are put in non-see through envelopes. These enve-
lopes can only be opened in the operating theatre just be-
fore timeout procedure, without informing the patient
about the outcome of randomisation
Blinding
The trial is a patient-blinded type. The patient is informed
on the type of mesh device used by means of the question-
naire after 24 months (P3). In the data handling phase of
the, the annalist is blinded for treatment. The consulted
physician during follow-up is not blind for the received
treatment.
Data outcome
A Verbal Descriptor Scale (VDS) is a scale of consecutive
descriptions. The following terms are used in the VDS
pain score, from which patients can choose to express the
level of pain: None, Mild, Moderate, Severe.
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Collected data: height, weight, VDS pain score at rest,
pain score while exercising and VDS cosmetic score, co-
morbidity and daily workload.
Questionnaire D1 – by the doctor – peroperative
Collected data: randomised device used (mesh/patch),
presence of incarceration, resection of the hernia protru-
sion, number of fingers for the width of the herniation
orifice, the need of widening the herniation orifice, closure
of fascia over mesh, presence of adhesions when placing
the device intraperitoneally, operation duration, VDS ease,
possible reasons protocol violation.
Questionnaire D2 – by the doctor – 1 month postoperative
Data collected are: complications, use of analgesics at that
time, VDS pain score at rest, pain score while exercising
and VDS cosmetic score.
Questionnaire P2 – by the patient – 3 months postoperative
Collected data: complications, recurrence, use of analge-
sics at that time, VDS pain score at rest, pain score while
exercising and VDS cosmetic score.
Questionnaire D3 – by the doctor – 1 year postoperative
Collected data: recurrence, use of analgesics at that time,
VDS pain score at rest, pain score while exercising and
VDS cosmetic score.
Questionnaire P3 – by the patient – 2 years postoperative
Collected data: recurrence, use of analgesics at that time,
VDS pain score at rest, pain score while exercising and
VDS cosmetic score.
Definitions
A complication is defined as an undesired development
that requires treatment, related to the operation site, oc-
curring within 3 months postoperative. Treatment could
also been initiated by the general practitioner, or other
than that by the hospital surgeon. Complications are
defined as following:
– Extending operation time due to bleeding or other
injury during the procedure
– Prescribed medication treatment such as antibiotics
and pain killers other than paracetamol after
discharge
– Re-operation such as evacuation of a haematoma,
drainage of an abscess, exploration related to pain or
intra-abdominal problems, or early recurrence
– Wound care which requires more than once a day
irrigation of the wound
– Hospitalisation longer than scheduled or
re-admissionThe costs will be calculated post-hoc on the basis of
the number of visits to the outpatient clinic, operation
duration, costs of prosthesis and complication-related
costs up to 2 years after the operation.Data collection methods
Completed informed consent forms remain at a central
location of the participating hospital. When participating
and signing, the patient receives a copy and the original
stays at the hospital.
Questionnaires P1 and P2 with return envelope are
given to the patient when he or she visits the outpatient
clinic. P3 (2 years postoperative) is sent from the coord-
inating research hospital.
Questionnaires for surgeons D1-3 are preferably en-
tered in an Excel/Access database on a hard disk access-
ible in the hospital. This can also be a paper version if
so desired.Data management
Completed informed consent forms must be faxed/
scanned/e-mailed to the coordinating research hospital.
The questionnaires use codes consisting of the first
initial and the first 2 letters of the last name followed by
the serial number of the participating hospital; this to
secure anonymity.
Informed consent forms and questionnaires remain in
one place at the participating hospital. A password is used
for the input program for surgeons.Statistical method
A p-value <0.05 is regarded as significant. SPSS statistics
will be used for processing.
Non-adherent data are not anticipated for this trial.
Prevention of missing values will be handled by telephone
checks. If any missing values remain, an analysis will be
made of the cause (completely at random/at random/
not at random). An intention to treat analysis will be
performed.
Comparison between the two interventions can be
subdivided in three periods; Pre-operative, per-operative
en post-operative comparison.Pre-operative
Body Mass Index (BMI), VDS pain score at rest, pain
score while exercising and VDS cosmetic score, comor-
bidity and daily workload. Differences in baseline charac-
teristics will be measured and presented in a baseline
characteristics table. The Mann–Whitney test is used for
continuous data and the Pearson’s chi-square/Fisher’s
exact test for categorical data.
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Presence of incarceration, resection of the hernia pro-
trusion, number of fingers for the width of the hernia-
tion orifice, the need of widening the herniation orifice,
closure of fascia over mesh, presence of adhesions when
placing the device intraperitoneally, operation duration,
VDS ease, possible reasons protocol violation. The Mann–
Whitney test is used for continuous data and the Pearson’s
chi-square/Fisher’s exact test for categorical data.
Post-operative
Occurrence of complications and pain score at rest and
pain score while exercising (VDS), the use of analgesics
at that time, cosmetic (VDS) and signs of recurrence
(1,3,12,24 months post-operative). The Mann–Whitney
test is used for continuous data and the Pearson’s chi-
square/Fisher’s exact test for categorical data. If possible
a Spearman’s correlations are used for analysis of rela-
tions between the (sub) groups (comorbidity, chronic post-
operative pain patients and recurrence).
Monitoring
A number of medical doctors and researchers contributing
in the trial will be inventoried in the starting phase of this
trial. Participating centres will be visited for explanation
trial. Local monitoring is in the hands of the local investi-
gator. The total overview of informed consent forms will
be up-to-date at the coordinating research hospital. Moni-
toring visits will be made by the surgeon-investigator de-
pending on the pace of inclusion.
Unexpected turns
Serious side effects and incidents, so-called SUSARs and
SAEs, should be reported to the central investigator
centre, which will make sure these are reported to the
ethics committees.
Interim analysis
No interim analysis is planned.
Ethical testing
After approval by local institutional review board
(Eindhoven), the protocol along with the name of the
surgeon from another hospital will be submitted for
local recommendations. Any amendments to the protocol
will initially be input at IRB Eindhoven by the principal
investigator.
Post-trial care
Care in the protocol exceeds the care customarily spent
in time. Since only general accepted techniques are used,
the hospital surgeon will be responsible for possible
long-term care.Co-investigators
Participating co-investigators will be asked to sign an
agreement in which the confidentiality of the data as
well as their commitment to the trial.
Publication
The plan is to create three publications. The primary
endpoint with short-term results will be processed in
one report. This will be one month post-operatively. The
the long-term results will be processed in two another
report. One report with one-year results and one with
two-year result. In the two-year results report, recur-
rence will be added as secondary outcome measure.
Co-investigators with a contribution of at least 10% of
the number of patients required will be asked for co-
authorship.
Discussion
This trial is one of the first in its kind, to compare differ-
ent sorts of mesh types in a randomized controlled set-
ting. Lots of mesh devices are available for herniorraphy
made by various companies. Often the choice of the mesh
depends on the personal favour of the operating surgeon.
The reason to start with this trial is to have a more scien-
tific approach for the decision-making regarding the deter-
mination of mesh device.
In this study protocol only the patient is blinded for
the treatment. By all means, the operating surgeon cannot
be blinded for the type of mesh. The doctor who sees the
patients in the outpatient clinic, and fills in forms D2 an
D3 can be blind for the treatment type. Because of logis-
tical reasons this is not added to this study protocol. Be-
sides the logistical reasons we think that there is little
value in blinding the treating doctor in the outpatient
clinic. Observer-bias will be very little because of the
straightforward multiple-choice questions in forms D2
and D3.
The results will help to evaluate mesh repair for epi-
gastric an umbilical hernia, and find a surgical device/
method that minimizes the complication rate. Besides
complication rate, recurrence and costs are taken in
account.
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